21241-09-8

Basic information

• Product Name: 4-methyl-N-[2-(6-methylpyridin-3-yl)ethyl]-N-nitrosoaniline
• Synonyms: 4-methyl-N-[2-(6-methylpyridin-3-yl)ethyl]-N-nitrosoaniline
• CAS NO: 21241-09-8
• Molecular Weight: 255.319
• Mol File: 21241-09-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-methyl-N-[2-(6-methylpyridin-3-yl)ethyl]-N-nitrosoaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-N-[2-(6-methylpyridin-3-yl)ethyl]-N-nitrosoaniline(21241-09-8)
• EPA Substance Registry System: 4-methyl-N-[2-(6-methylpyridin-3-yl)ethyl]-N-nitrosoaniline(21241-09-8)

Safety Data

• Hazardous Substances Data: 21241-09-8(Hazardous Substances Data)

Upstream product

• 21241-10-1 4-methyl-N-(2-(6-methylpyridin-3-yl)ethyl)aniline 
• 52426-67-2 2-(6-methylpyridin-3-yl)acetonitrile 
• 34107-46-5 6-methyl-3-pyridinemethanol 
• 19733-95-0 4-[(6-methyl-pyridin-3-yl)-thioacetyl]-morpholine 
• 36357-38-7 1-(6-methyl-pyridin-3-yl)-ethanone 
• 19733-96-1 2-(6-methylpyridin-3-yl)acetic acid 
• 106-49-0 p-toluidine 

Downstream Products

• 21241-08-7 2-methyl-5-{2-[1-(4-methylphenyl)hydrazinyl]ethyl}pyridine 
• 1229621-60-6 N'-(1-methyl-piperidin-4-ylidene)-N-[2-(6-methyl-pyridin-3-yl)-ethyl]-N-p-tolyl-hydrazine 
• 3613-73-8 dimebon 

Relevant articles and documents

[11C]Dimebon, radiosynthesis and lipophilicity of a new potential PET agent for imaging of Alzheimer's disease and Huntington's disease

[11C]Dimebon (2-[11C]methyl-8-methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3 ,4,5-tetrahydro-1H-pyrido[4,3-b]indole), a new potential PET agent for imaging of Alzheimer's disease and Huntington's disease, was prepared by N-[11C]methylation of desmethyl-Domebon precursor with [11C]CH3OTf and purified with a semi-preparative HPLC method in 30-40% decay corrected radiochemical yield and 222-296 GBq/μmol specific activity at EOB. The measured lipophilicity coefficient (Log P) value of [11C]Dimebon was 2.53.

SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO Y4, 3-b¨INDOLE DERIVATIVE AND PREPARATION METHOD OF DERIVATIVE

The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.

SYNTHESIS OF 9-(ARYLALKYL)-1,2,3,4-TETRAHYDRO-Υ-CARBOLINE AND ANALOGUES AND INTERMEDIATES

The present invention pertains generally to methods of preparing certain 9-(arylalkyl)- 1,2,3,4-tetrahydro-Υ-carboline compounds and their analogues, and especially to methods of preparing dimebon. The present invention also pertains to methods of preparing certain intermediate compounds which find use in the synthesis of the 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline compounds.